

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	Mueller, Peter S.	Examiner:	Unassigned
Serial No.:	Unassigned	Group Art Unit:	Unassigned
Confirmation No:	Unassigned	Docket:	893-2 CIP II/DIV
Filed:	Herewith	Dated:	December 31, 2003
For:	TREATMENT OF DISORDERS SECONDARY TO ORGANIC IMPAIRMENT		

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

*I hereby certify this correspondence is being deposited
with the United States Postal Service in an envelope as
"Express Mail to Addressee" Mailing Label No.
EV261771207US, addressed to: Mail Stop Patent
Application, Commissioner for Patents,
Commissioner for Patents, P.O. Box 1450,
Alexandria, Virginia 22313-1450
on December 31, 2003*

Signed: _____

Nancy C. Marcovici
Nancy C. Marcovici

INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R.

§1.56, Applicants submit herewith the following Information Disclosure Statement in
accordance with the provisions of 37 C.F.R. §1.97 and §1.98.


This application is a divisional of co-pending U.S. Application No. 10/092,144, filed
March 6, 2002, which is a continuation-in-part of U.S. Patent Application No. 09/836,156,
filed April 17, 2001, which is a continuation-in-part application of U.S. Patent Application
No. 09/204,124, filed December 2, 1998. Copies of the references cited herein have been
previously submitted to the USPTO for the related application or have been cited in the

related application. In accordance with 37 C.F.R. §1.98(d), copies of these references are not provided herein.

Since this Information Disclosure Statement is being submitted before the issuance of a first Office Action, no fee is believed to be necessary. If, however, a fee is necessary, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 08-2461.

If the Examiner has any questions or comments relating to the present application, he or she is respectfully invited to contact Applicants' agent at the telephone number set forth below.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Anna-Lisa Gallo', written over a horizontal line.

Anna-Lisa Gallo

Registration No.: 50,279

Attorney for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(973) 331-1700

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 893-2 CIP II DIV	SERIAL NO. Unassigned
	APPLICANT Mueller, Peter S.	CONFIRMATION NO. Unassigned
	FILING DATE Unassigned	GROUP Unassigned

U.S. PATENT PUBLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
		6,075,028	06/13/00	Graham			
		5,985,866	11/16/99	Müller et al.			
		5,922,341	07/13/99	Smith et al.			
		5,908,830	06/01/99	Smith et al.			
		5,804,596	09/08/98	Majeed et al.			
		5,795,880	08/18/98	Svec et al.			
		5,780,051	07/14/98	Eswara et al.			
		5,773,436	06/30/98	Müller et al.			
		5,668,117	09/16/97	Shapiro			
		5,643,916	07/01/97	Audia et al.			
		5,589,512	12/31/96	Norden			
		5,459,164	10/17/95	Vargas			
		5,436,272	07/25/95	Scheinbaum			
		4,939,175	07/03/90	Ukal et al.			
		4,929,629	05/29/90	Jeffery			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 893-2 CIP II DIV	SERIAL NO. Unassigned
	APPLICANT Mueller, Peter S.	CONFIRMATION NO. Unassigned
	FILING DATE Unassigned	GROUP Unassigned

		4,871,774	10/03/89	Rees			
		4,816,488	03/28/89	Rees			
		4,814,352	03/21/89	Jeffery et al.			
		4,806,570	02/21/89	Jeffery et al.			
		4,767,790	08/30/88	Jeffery et al.			
		4,746,680	05/24/88	Jeffery et al.			
		4,522,828	06/11/85	Jeffery et al.			
		4,443,449	04/17/84	Jeffery et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
		EPO 0 339 280	11/02/89	EPO				
		WO 00/10551	03/02/00	PCT				
		WO 98/13034	04/02/98	PCT				
		WO 98/11884	03/28/98	PCT				
		WO 95/21615	08/17/95	PCT				
		WO 94/00114	01/06/94	PCT				
		WO 94/00047	01/06/94	PCT				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 893-2 CIP II DIV	SERIAL NO. Unassigned
	APPLICANT Mueller, Peter S.	CONFIRMATION NO. Unassigned
	FILING DATE Unassigned	GROUP Unassigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			1. R. T. Malison et al., <i>Am. J. Psychiatry</i> , 152(9): 1359-1361 (1995).
			2. T. M. Hyde et al., <i>JAMA</i> 273:498-501 (1995).
			3. S. Lipper et al., <i>Psychosomatics</i> , 27(12): 849-854 (1986).
			4. R. M. Post, <i>Clin. Neuropharmacol</i> , 2:25-42 (1977).
			5. E. M. Ornitz et al., <i>Am. J. Psychiatry</i> , 146(7): 866-870 (1989).
			6. <i>Psychiatric Annals</i> , 28:4240468 (1998). (a) L. Izrayelit; (b) J. Fawcett; (c) C. A. Morgan et al.; (d) S. M. Southwick et al.; (e) J. D. Bremner; (f) D. S. Lipshitz et al.; (g) M. J. Friedman
			7. Devinsky et al., <i>Neurology</i> , 39:835-840 (1989).
			8. R. W. Cowdry et al., <i>Arch. Gen. Psychiatry</i> , 45:111-119 (1988).
			9. Yudofsky et al., <i>Am. J. Psychiatry</i> , 138:218-220 (1981).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 893-2 CIP II DIV	SERIAL NO. Unassigned
	APPLICANT Mueller, Peter S.	CONFIRMATION NO. Unassigned
	FILING DATE Unassigned	GROUP Unassigned

			10. J. Fawcett, <i>Psychiatric Annuals</i> , 27(11): 725 (1997).
			11. D. M. Bear, <i>Cortex</i> , 15:357-384 (1979).
			12. W. W. Beaty and N. Monson, <i>Journal of the International Neurological Society</i> , 2:134-140 (1996).
			13. V. Goel and P. Grafman, <i>Neuropsychologia</i> , 33(5):623-624 (1995).
			14. K. Fukuda et al., <i>Ann. Intern Med.</i> , 121:953-959 (1994).
			15. A. L. Komaroff et al., <i>Rev. Infect. Dis.</i> , 13 (Supp.): S8-11 (1991).
			16. A. I. Komaroff et al., <i>Am. J. Med.</i> , 101:281-290 (1996).
			17. L. J. Kirmayer et al., <i>Am. J. Psychiatry</i> , 145:950-954 (1988).
			18. E. J. Khantzian, <i>Am. J. Psychiatry</i> , 142:1259-1264 (1985).
			19. "The Silent Epidemic: Rehabilitation of People with Traumatic Brain Injury", <i>Rehab Brief</i> , Vol. IX, No. 4 (undated).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 893-2 CIP II DIV	SERIAL NO. Unassigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Mueller, Peter S.	CONFIRMATION NO. Unassigned
(Use several sheets if necessary)	FILING DATE Unassigned	GROUP Unassigned

			20. C. Reist, et al., <i>J. Psychiatry</i> , 146:513-516 (1989).
			21. A. M. Gray et al., "The Involvement of the Opioidergic System in the Antinociceptive Mechanism of Action of Antidepressant Compounds," <i>British Journal of Pharmacology</i> , 124, 669-674 (1998).
			22. "New Approaches to Treating A Perplexing Pain Disorder", <i>HealthNews</i> , 1-2 (October 2000).
			23. R. J. Schwartzman, "New Treatments for Reflex Sympathetic Dystrophy", <i>The New England Journal of Medicine</i> , 654-656 (August 31, 2000).
			24. "The Persistent Problem of Cystic Fibrosis", <i>Science News</i> , Vol. 161, pp. 59-60 (January 26, 2002).
			25. "Reflex Sympathetic Dystrophy", <i>Neurological Review</i> , Vol. 44 (May 1987).
			26. G. Greenberg, "The Serotonin Surprise", <i>Discover</i> , pp. 65-67 (July 2001).
			27. A Truscott, "Doubling and Redoubling Requires Deft Maneuvering", <i>The New York Times</i> , (August 27, 2001).
			28. D. Starlanyl, MD, "Guide to Medications for Fibromyalgia", <i>Health Watch Newsletter</i> , Volume X, No. 2 (2001).
			29. E. Ross, MD, "New Approaches to Treating a Perplexing Pain Disorder", <i>Health News</i> , (October 2000).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 893-2 CIP II DIV	SERIAL NO. Unassigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Mueller, Peter S.	CONFIRMATION NO. Unassigned
		FILING DATE Unassigned	GROUP Unassigned

			30. B. G. Brown, MD, et al., "Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease". <i>The New England Journal of Medicine</i> , Volume 345, Number 22 (November 29, 2002).
			31. E. Goode, "Treatment Can Ease Lingering Trauma of Sept. 11", <i>Science Times</i> , The New York Times, (November 20, 2001).
			32. R. J. Ursano, MD, "Post-Traumatic Stress Disorder", <i>New England Journal of Medicine</i> , Vol. 346, No. 2 (January 10, 2002).
			33. K. B. Nelson, et al., "Obstetric Complications as Risk Factors for Cerebral Palsy or Seizure Disorders", <i>JAMA</i> , Vol. 251, No. 14 (April 13, 1984).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.